Mohammadaref Ghaderi

Mohammadaref Ghaderi


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
AHArvin Honari
Arvin Honari
DMDarrah A. Merillat
Darrah A. Merillat
ABAditi Bellary
Aditi Bellary
MGMohammadaref Ghaderi
Mohammadaref Ghaderi
SSShashank R. Sirsi
Shashank R. Sirsi
Active targeted delivery of small molecule drugs is becoming increasingly important in personalized therapies, especially in cancer, brain disorders, and a wide variety of other diseases. However, effective means of spatial targeting and delivering high drug payloads in vivo are still lacking. Focused ultrasound combined with superheated phase-shift nanodroplets, which vaporize into microbubbles using heat and sound, are rapidly becoming a popular strategy for targeted drug delivery. Focused ultrasound can target deep tissue with excellent spatial precision and without using ionizing energy, thus can activate nanodroplets in circulation. One of the main limitations of this technology has been poor drug loading in the droplet core or the shell material. To address this need, we have developed a strategy to combine low-boiling point decafluorabutane and octafluoropropane (DFB and OFP) nanodroplets with drug-loaded liposomes, creating phase-changeable droplet-liposome clusters (PDLCs). We demonstrate a facile method of assembling submicron PDLCs with high drug-loading capacity on the droplet surface. Furthermore, we demonstrate that chemical tethering of liposomes in PDLCs enables a rapid release of their encapsulated cargo upon acoustic activation (>60% using OFP-based PDLCs). Rapid uncaging of small molecule drugs would make them immediately bioavailable in target tissue or promote better penetration in local tissue following intravascular release. PDLCs developed in this study can be used to deliver a wide variety of liposome-encapsulated therapeutics or imaging agents for multi-modal imaging applications. We also outline a strategy to deliver a surrogate encapsulated drug, fluorescein, to tumors in vivo using focused ultrasound energy and PDLCs.

6 August 2026 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
MMMendi Marquez
Mendi Marquez
FFFernando Flores-Guzman
Fernando Flores-Guzman
IIIsabella Iwanicki
Isabella Iwanicki
LWLydia Wu
Lydia Wu
JVJacky Villa-Gomez
Jacky Villa-Gomez
SHSonia L. Hernandez
Sonia L. Hernandez